Berk Justin, Brar Jessica, Hoadley Ariel, Martin Rosemarie
Department of Medicine, Alpert Medical School, Brown University, Providence, RI, USA.
Department of Social and Behavioral Sciences, Temple College of Public Health, Philadelphia, PA, USA.
Subst Use Addctn J. 2025 Jan;46(1):64-71. doi: 10.1177/29767342241273417. Epub 2024 Sep 2.
The opioid overdose crisis significantly affects marginalized communities, with people of color experiencing higher rates of overdose and barriers to treatment. The syndemic of opioid use disorder and mass incarceration exacerbates racial health disparities. Some carceral facilities offer medication for addiction treatment, though no significant research explores differences in type of treatment uptake by race in these settings. This study focuses on the racial differences in medications for opioid use disorder (MOUD) preferences among incarcerated individuals.
A retrospective cohort study was conducted at the Rhode Island Department of Corrections (RIDOC), examining MOUD-type preferences (buprenorphine or methadone) among incarcerated individuals. The study utilized RIDOC electronic medical records from January 1, 2017 to December 31, 2022, involving 3533 unique incarceration events. Participants were categorized by race (White vs non-White) and MOUD status (new initiation vs community continuation), with logistic regression models.
The study found no direct racial disparity in preferences for MOUD type. However, an interaction between race and MOUD initiation status significantly influenced MOUD-type preference. Among those initiating MOUD during incarceration, non-White individuals were more likely to choose buprenorphine compared to their White counterparts.
This research provides new insights into the intersection of race, incarceration, and MOUD preferences. While direct racial disparities in MOUD type were not observed, the analysis uncovered a notable interaction effect: race influences the relationship between MOUD initiation status and the selected MOUD treatment during incarceration. Specifically, data demonstrate that the likelihood of choosing buprenorphine varies significantly based on both racial background and whether the treatment was initiated during incarceration or in the community. Further research is needed in different geographic settings to understand the broader implications to help guide equitable healthcare delivery in jails and prisons.
阿片类药物过量危机对边缘化社区产生了重大影响,有色人种的过量用药率更高,且面临治疗障碍。阿片类药物使用障碍和大规模监禁的并发加剧了种族健康差距。一些监狱设施提供成瘾治疗药物,不过尚无显著研究探讨在这些环境中按种族划分的治疗接受类型差异。本研究聚焦于被监禁者在阿片类药物使用障碍(MOUD)药物偏好方面的种族差异。
在罗德岛惩教部(RIDOC)进行了一项回顾性队列研究,调查被监禁者对MOUD类型(丁丙诺啡或美沙酮)的偏好。该研究利用了RIDOC从2017年1月1日至2022年12月31日的电子病历,涉及3533次独特的监禁事件。参与者按种族(白人对非白人)和MOUD状态(新开始治疗对社区延续治疗)进行分类,并采用逻辑回归模型。
该研究发现,在MOUD类型偏好方面不存在直接的种族差异。然而,种族与MOUD开始状态之间的相互作用显著影响了MOUD类型偏好。在监禁期间开始使用MOUD的人群中,与白人相比,非白人个体更有可能选择丁丙诺啡。
本研究为种族、监禁和MOUD偏好的交叉点提供了新的见解。虽然未观察到MOUD类型方面的直接种族差异,但分析发现了一个显著的相互作用效应:种族影响监禁期间MOUD开始状态与所选MOUD治疗之间的关系。具体而言,数据表明,选择丁丙诺啡的可能性因种族背景以及治疗是在监禁期间还是社区中开始而有显著差异。需要在不同地理环境中进行进一步研究,以了解更广泛的影响,从而帮助指导监狱中的公平医疗服务提供。